Published in Am J Pathol on September 01, 1993
Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med (2012) 6.15
Integrating mechanisms of pulmonary fibrosis. J Exp Med (2011) 3.57
Alveolar epithelial type II cell: defender of the alveolus revisited. Respir Res (2001) 3.26
Tumor necrosis factor-alpha overexpression in lung disease: a single cause behind a complex phenotype. Am J Respir Crit Care Med (2005) 2.56
Expression of a tumor necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive pulmonary fibrosis. J Clin Invest (1995) 2.20
Pulmonary cytomegalovirus reactivation causes pathology in immunocompetent mice. Crit Care Med (2006) 1.92
The molecular basis of asbestos induced lung injury. Thorax (1999) 1.82
Transfer of tumor necrosis factor-alpha to rat lung induces severe pulmonary inflammation and patchy interstitial fibrogenesis with induction of transforming growth factor-beta1 and myofibroblasts. Am J Pathol (1998) 1.82
Growth factors in idiopathic pulmonary fibrosis: relative roles. Respir Res (2001) 1.55
Different effects of growth factors on proliferation and matrix production of normal and fibrotic human lung fibroblasts. Lung (2005) 1.42
Soluble TNF mediates the transition from pulmonary inflammation to fibrosis. PLoS One (2006) 1.32
Interstitial fibrosis and growth factors. Environ Health Perspect (2000) 1.32
Novel therapeutic approaches for pulmonary fibrosis. Br J Pharmacol (2011) 1.24
Smooth muscle alpha-actin expression and myofibroblast differentiation by TGFbeta are dependent upon MK2. J Cell Biochem (2007) 1.20
Innate immune responses to bacterial ligands in the peripheral human lung--role of alveolar epithelial TLR expression and signalling. PLoS One (2011) 1.09
Lack of MK2 inhibits myofibroblast formation and exacerbates pulmonary fibrosis. Am J Respir Cell Mol Biol (2007) 1.01
The distribution of immunomodulatory cells in the lungs of patients with idiopathic pulmonary fibrosis. Mod Pathol (2011) 0.96
Effects of Mycobacterium tuberculosis on the bioelectric properties of the alveolar epithelium. Infect Immun (1997) 0.94
Pharmacological inhibition of leukotrienes in an animal model of bleomycin-induced acute lung injury. Respir Res (2006) 0.94
The pro-fibrotic factor IGFBP-5 induces lung fibroblast and mononuclear cell migration. Am J Respir Cell Mol Biol (2009) 0.93
Idiopathic pulmonary fibrosis : new concepts in pathogenesis and implications for drug therapy. Treat Respir Med (2006) 0.90
Idiopathic pneumonia syndrome after bone marrow transplantation: the role of pre-transplant radiation conditioning and local cytokine dysregulation in promoting lung inflammation and fibrosis. Int J Exp Pathol (2001) 0.89
Hepatocyte growth factor in lung repair and pulmonary fibrosis. Acta Pharmacol Sin (2010) 0.87
The safety of biologic therapies in RA-associated interstitial lung disease. Nat Rev Rheumatol (2013) 0.85
Analyzing the genes and peptide growth factors expressed in lung cells in vivo consequent to asbestos exposure and in vitro. Environ Health Perspect (1997) 0.84
Evidence for a functional thymic stromal lymphopoietin signaling axis in fibrotic lung disease. J Immunol (2013) 0.83
Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis. BMJ Open (2014) 0.83
Boswellic acids extract attenuates pulmonary fibrosis induced by bleomycin and oxidative stress from gamma irradiation in rats. Chin Med (2011) 0.83
Protective Effect of Infliximab, a Tumor Necrosis Factor-Alfa Inhibitor, on Bleomycin-Induced Lung Fibrosis in Rats. Inflammation (2016) 0.82
Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice. BMC Pulm Med (2010) 0.82
Pharmacologic therapies for idiopathic pulmonary fibrosis, past and future. Ann Med (2015) 0.81
Matrix Remodeling in Pulmonary Fibrosis and Emphysema. Am J Respir Cell Mol Biol (2016) 0.80
Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib. Drug Des Devel Ther (2015) 0.79
Interaction between human lung fibroblasts and T-lymphocytes prevents activation of CD4+ cells. Respir Res (2005) 0.79
Inflammatory response mechanisms exacerbating hypoxemia in coexistent pulmonary fibrosis and sleep apnea. Mediators Inflamm (2015) 0.77
Apigenin protects against bleomycin-induced lung fibrosis in rats. Exp Ther Med (2015) 0.77
Increased expression of ICAM-1 and VCAM-1 in the lung of nitrofen-induced congenital diaphragmatic hernia in rats. Pediatr Surg Int (2003) 0.76
Prostaglandin D2 Attenuates Bleomycin-Induced Lung Inflammation and Pulmonary Fibrosis. PLoS One (2016) 0.75
Intrinsic defence capacity and therapeutic potential of natriuretic peptides in pulmonary hypertension associated with lung fibrosis. Br J Pharmacol (2014) 0.75
Magnolol reduces bleomycin-induced rodent lung fibrosis. Int J Clin Exp Med (2015) 0.75
Establishment of a mouse model for pulmonary inflammation and fibrosis by intratracheal instillation of polyhexamethyleneguanidine phosphate. J Toxicol Pathol (2016) 0.75
Anti-TNFα Therapy in Inflammatory Lung Diseases bn. Pharmacol Ther (2017) 0.75
Antifibrotic role of HGF in sarcoidosis. Lung (2012) 0.75
Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science (1986) 9.19
Gamma interferon enhances macrophage transcription of the tumor necrosis factor/cachectin, interleukin 1, and urokinase genes, which are controlled by short-lived repressors. J Exp Med (1986) 5.09
Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci U S A (1991) 4.61
Cloning and sequencing of a deoxyribonucleic acid copy of glyceraldehyde-3-phosphate dehydrogenase messenger ribonucleic acid isolated from chicken muscle. Biochemistry (1983) 4.28
Interstitial lung disease: current concepts of pathogenesis, staging and therapy. Am J Med (1981) 3.08
Human keratinocytes are a source for tumor necrosis factor alpha: evidence for synthesis and release upon stimulation with endotoxin or ultraviolet light. J Exp Med (1990) 2.62
Platelet-derived growth factor in idiopathic pulmonary fibrosis. J Clin Invest (1990) 2.29
Molecular cloning and expression of human tumor necrosis factor and comparison with mouse tumor necrosis factor. Eur J Biochem (1985) 1.99
Plasminogen activators in tissue remodeling and invasion: mRNA localization in mouse ovaries and implanting embryos. J Cell Biol (1989) 1.88
Direct evidence for an intracellular role for tumor necrosis factor-alpha 1. Microinjection of tumor necrosis factor kills target cells. J Immunol (1990) 1.22
TNF in autoimmune diseases, graft-versus-host reactions, and pulmonary fibrosis. Immunol Ser (1992) 0.89
The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell (1989) 10.98
Tumor necrosis factor (cachectin) as an essential mediator in murine cerebral malaria. Science (1987) 7.01
Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med (1988) 4.69
Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J Exp Med (1987) 3.62
Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J Exp Med (1989) 3.58
Requirement of tumour necrosis factor for development of silica-induced pulmonary fibrosis. Nature (1990) 3.46
Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med (2001) 3.40
Updated Kiel classification for lymphomas. Lancet (1988) 3.25
In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest (1999) 3.19
Pathogenesis and reversibility of the pulmonary lesions of oxygen toxicity in monkeys. II. Ultrastructural and morphometric studies. Lab Invest (1969) 3.01
Immunochemical identification of intermediate-sized filaments in human neoplastic cells. A diagnostic aid for the surgical pathologist. Am J Pathol (1981) 2.94
L3T4+ T lymphocytes play a major role in the pathogenesis of murine cerebral malaria. J Immunol (1986) 2.79
Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica. Cytokine (1993) 2.48
Anti-TNF therapy inhibits fever in cerebral malaria. Q J Med (1993) 2.47
Morphological and immunochemical differences between keloid and hypertrophic scar. Am J Pathol (1994) 2.44
Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock. Swiss-Dutch J5 Immunoglobulin Study Group. J Infect Dis (1990) 2.36
Dynamics of fever and serum levels of tumor necrosis factor are closely associated during clinical paroxysms in Plasmodium vivax malaria. Proc Natl Acad Sci U S A (1992) 2.34
Tumor necrosis factor is a critical mediator in hapten induced irritant and contact hypersensitivity reactions. J Exp Med (1991) 2.24
Expression of a tumor necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive pulmonary fibrosis. J Clin Invest (1995) 2.20
"Contractile interstitial cells" in pulmonary alveolar septa: a possible regulator of ventilation-perfusion ratio? Ultrastructural, immunofluorescence, and in vitro studies. J Cell Biol (1974) 2.11
High bronchoalveolar levels of tumor necrosis factor and its inhibitors, interleukin-1, interferon, and elastase, in patients with adult respiratory distress syndrome after trauma, shock, or sepsis. Am Rev Respir Dis (1992) 2.05
Serum levels of tumour necrosis factor-alpha and interleukin-1 beta during leprosy reactional states. Clin Exp Immunol (1991) 1.94
Pathogenesis of cerebral malaria: recent experimental data and possible applications for humans. Clin Microbiol Rev (2001) 1.91
Profiles of cytokine production in relation with susceptibility to cerebral malaria. J Immunol (1993) 1.77
Interleukin-10 modulates susceptibility in experimental cerebral malaria. Immunology (1997) 1.73
Cytokines kill malaria parasites during infection crisis: extracellular complementary factors are essential. J Exp Med (1991) 1.69
Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology (1992) 1.63
Role of TNF and IL-1 in infections with Toxoplasma gondii. Immunology (1990) 1.61
Crucial role of tumor necrosis factor (TNF) receptor 2 and membrane-bound TNF in experimental cerebral malaria. Eur J Immunol (1997) 1.56
A case of Encephalitozoon cuniculi peritonitis in a patient with AIDS. Am J Clin Pathol (1989) 1.55
Subcutaneous perfusion of tumor necrosis factor induces local proliferation of fibroblasts, capillaries, and epidermal cells, or massive tissue necrosis. Am J Pathol (1990) 1.53
Transgenic mice expressing high levels of soluble TNF-R1 fusion protein are protected from lethal septic shock and cerebral malaria, and are highly sensitive to Listeria monocytogenes and Leishmania major infections. Eur J Immunol (1995) 1.45
Rat alveolar myofibroblasts acquire alpha-smooth muscle actin expression during bleomycin-induced pulmonary fibrosis. Am J Pathol (1993) 1.44
Nitric oxide and cerebral malaria. Lancet (1993) 1.43
Immunopathological changes in human cerebral malaria. Clin Neuropathol (1993) 1.40
Oxygen pneumonitis in man. Ultrastructural observations on the development of alveolar lesions. Lab Invest (1972) 1.37
Platelets play an important role in TNF-induced microvascular endothelial cell pathology. Am J Pathol (1997) 1.35
Role of polymorphonuclear neutrophil leukocytes and their integrin CD11a (LFA-1) in the pathogenesis of severe murine malaria. Infect Immun (1994) 1.35
Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites. Am J Trop Med Hyg (1993) 1.34
Tumor necrosis factor and severe malaria. J Infect Dis (1991) 1.34
Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood (1998) 1.32
Pathogenesis and reversibility of the pulmonary lesions of oxygen toxicity in monkeys. I. Clinical and light microscopic studies. Lab Invest (1969) 1.31
Tumor necrosis factor in the pathogenesis of infectious diseases. Crit Care Med (1993) 1.29
Tumour necrosis factor-dependent parasite-killing effects during paroxysms in non-immune Plasmodium vivax malaria patients. Clin Exp Immunol (1992) 1.29
Anti-parasite effects of cytokines in malaria. Immunol Lett (1990) 1.28
Acute systemic reaction and lung alterations induced by an antiplatelet integrin gpIIb/IIIa antibody in mice. Blood (1999) 1.25
Prediction of accelerated cure in Plasmodium falciparum malaria by the elevated capacity of tumor necrosis factor production. Am J Trop Med Hyg (1995) 1.21
Plasma concentrations of cytokines, their soluble receptors, and antioxidant vitamins can predict the development of multiple organ failure in patients at risk. Crit Care Med (1996) 1.19
Contractile proteins in human cancer cells. Immunofluorescent and electron microscopic study. Am J Pathol (1976) 1.18
Imbalance between tumour necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia. The J5 Study Group. Immunology (1992) 1.16
Role of platelet adhesion in homeostasis and immunopathology. Mol Pathol (1997) 1.16
Characterization of stromal cells with myoid features in lymph nodes and spleen in normal and pathologic conditions. Am J Pathol (1987) 1.15
TNF inhibition and sepsis -- sounding a cautionary note. Nat Med (1997) 1.13
TNF receptors in the microvascular pathology of acute respiratory distress syndrome and cerebral malaria. J Leukoc Biol (1997) 1.12
An effector role for platelets in systemic and local lipopolysaccharide-induced toxicity in mice, mediated by a CD11a- and CD54-dependent interaction with endothelium. Infect Immun (1993) 1.12
Both TNF receptors are required for direct TNF-mediated cytotoxicity in microvascular endothelial cells. Eur J Immunol (1998) 1.11
Oxygen pneumonitis in man., Light- and electron-microscopic morphometric studies. Chest (1972) 1.11
Cytoskeletal features of alveolar myofibroblasts and pericytes in normal human and rat lung. J Histochem Cytochem (1992) 1.11
T lymphocyte interferon-gamma production induced by Plasmodium falciparum antigen is high in recently infected non-immune and low in immune subjects. Clin Exp Immunol (1990) 1.09
Correlation of tumor necrosis factor levels in the serum and cerebrospinal fluid with clinical outcome in Japanese encephalitis patients. J Med Virol (1997) 1.09
Tumor necrosis factor in Plasmodium falciparum malaria: high plasma level is associated with fever, but high production capacity is associated with rapid fever clearance. Eur Cytokine Netw (1997) 1.09
Role of cytokines and adhesion molecules in malaria immunopathology. Stem Cells (1993) 1.09
Circulating plasma receptors for tumour necrosis factor in Malawian children with severe falciparum malaria. Cytokine (1993) 1.09
TNF inhibits malaria hepatic stages in vitro via synthesis of IL-6. Int Immunol (1991) 1.07
Demonstration of anti-disease immunity to Plasmodium vivax malaria in Sri Lanka using a quantitative method to assess clinical disease. Am J Trop Med Hyg (1998) 1.06
[Cellular (juvenile) fibroadenoma of the breast. A clinico-pathologic and immunohistochemical study of 7 cases]. Ann Pathol (1994) 1.06
Respective role of TNF receptors in the development of experimental cerebral malaria. J Neuroimmunol (1997) 1.04
Delayed mortality and attenuated thrombocytopenia associated with severe malaria in urokinase- and urokinase receptor-deficient mice. Infect Immun (2000) 1.03
Differential reactivity of brain microvascular endothelial cells to TNF reflects the genetic susceptibility to cerebral malaria. Eur J Immunol (1998) 1.00
Effective treatment of the pulmonary fibrosis elicited in mice by bleomycin or silica with anti-CD-11 antibodies. Am Rev Respir Dis (1993) 0.99
Pneumopathies of the graft-versus-host reaction. Alveolitis associated with an increased level of tumor necrosis factor mRNA and chronic interstitial pneumonitis. Lab Invest (1989) 0.99
Tumor necrosis factor and immunopathology. Immunol Res (1991) 0.98
Assaying tumor necrosis factor concentrations in human serum. A WHO International Collaborative study. J Immunol Methods (1995) 0.98
Tumour necrosis factor, interleukin-6, and malaria. Lancet (1991) 0.97
The lectin-like domain of tumor necrosis factor-alpha increases membrane conductance in microvascular endothelial cells and peritoneal macrophages. Eur J Immunol (1999) 0.96
Histopathologic features of hepatocellular carcinoma in Zaire. Cancer (1990) 0.95
Plasma cytokine levels in hemolytic uremic syndrome. Nephron (1995) 0.95
Contribution of tumor necrosis factor to host defense against staphylococci in a guinea pig model of foreign body infections. J Infect Dis (1992) 0.95
Analytical performances of commercial ELISA-kits for IL-2, IL-6 and TNF-alpha. A WHO study. Eur Cytokine Netw (1994) 0.93
Altered functions of peripheral blood monocytes in homosexual males and intravenous drug users with persistent generalized lymphadenopathy. Eur J Clin Invest (1986) 0.93
Direct cell/cell contact with stimulated T lymphocytes induces the expression of cell adhesion molecules and cytokines by human brain microvascular endothelial cells. Eur J Immunol (1996) 0.93
Respective role of polymorphonuclear leukocytes and their integrins (CD-11/18) in the local or systemic toxicity of lipopolysaccharide. J Leukoc Biol (1993) 0.93
Tumor necrosis factor alpha is involved in mouse growth and lymphoid tissue development. J Exp Med (1992) 0.93
Expression of major histocompatibility complex antigens on mouse brain microvascular endothelial cells in relation to susceptibility to cerebral malaria. Immunology (1997) 0.93
Serum tumour necrosis factor in newborns at risk for infections. Eur J Pediatr (1990) 0.93
Lupoid hepatitis following administration of penicillin. Case report and immunological studies. Helv Med Acta (1967) 0.91
Interferon-beta inhibits activated leukocyte migration through human brain microvascular endothelial cell monolayer. Lab Invest (1999) 0.91
Serum tumor necrosis factor and interleukin 1 in leprosy and during lepra reactions. Clin Immunol Immunopathol (1992) 0.89
TNF in autoimmune diseases, graft-versus-host reactions, and pulmonary fibrosis. Immunol Ser (1992) 0.89
H-2D haplotype-linked expression and involvement of TNF-alpha in Th2 cell-mediated tissue inflammation. J Immunol (1994) 0.89
[Histologic and immunohistochemical profiles of benign granular cell tumors. Report of 41 cases]. Ann Pathol (1995) 0.88
An improved method for isolation of microvascular endothelial cells from normal and inflamed human lung. In Vitro Cell Dev Biol Anim (1998) 0.88
Diffuse interstitial lung disease associated with hydrogen peroxide inhalation in a dairy worker. Am Rev Respir Dis (1988) 0.87
Pathogenesis of the delayed phase of Rauscher virus-induced thrombocytopenia. J Immunol (1986) 0.87
[Malignant paraganglioma of the duodenum. Immunohistochemical and ultrastructural study of a case]. Ann Pathol (1987) 0.87
Stabilisation of functional tumor necrosis factor-alpha by its soluble TNF receptors. Eur Cytokine Netw (1994) 0.87
Expression and release of tumor necrosis factor-alpha by explants of mouse cornea. Invest Ophthalmol Vis Sci (1996) 0.86